Atlantic Health System | Strategic Alliance Partners

Joshua Strauss, MD, discusses future research directions for the treatment of patients with small cell lung cancer.

Neil Morganstein, MD, discusses the mechanism of action of lurbinectedin in metastatic small cell lung cancer.

Neil Morganstein, MD, discusses the impact of lurbinectedin on the SCLC treatment paradigm and future research directions with the agent in this population.

Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses ways to expand the benefit of immunotherapy in non-immunogenic solid tumors.

Missak Haigentz, MD, chief of Hematology and Oncology at Morristown Medical Center and medical director of Atlantic Hematology and Oncology for Atlantic Medical Group at the Carol G. Simon Cancer Center, discusses the potential of erlotinib (Tarceva) and bevacizumab (Avastin) in EGFR-mutant non–small cell lung cancer (NSCLC).

Balazs Halmos, MD, discusses the latest developments in the treatment paradigm for patients with squamous cell non–small cell lung cancer.

Missak Haigentz, MD, discusses the impact of EGFR TKIs on the treatment of patients with non–small cell lung cancer.

Neil Morganstein, MD, discusses the intriguing PACIFIC results and the future role of immunotherapy in non–small cell lung cancer.

Mark Widmann, MD, discusses the role of surgery in the treatment of patients with early-stage lung cancer.

Hossein Borghaei, DO, MS, discusses immunotherapy selection for the treatment of patients with non–small cell lung cancer.

Ramsey N. Asmar, MD, discusses recent advances and next steps in small cell lung cancer.

P. Cosmo Smith, MBA, managing partner, Origin Commercial Ventures, discusses The Breakthrough Oncology Accelerator flagship program.

Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses eliminating financial toxicity in oncology.

P. Cosmo Smith, managing partner, Origin Commercial Ventures, discusses how Origin improves patient access in oncology.

Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses improving precision medicine in oncology.

P. Cosmo Smith, MBA, managing partner, Origin Commercial Ventures, discusses the difference between clinical liquidity and financial liquidity.

Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses the partnership between Atlantic Health System, Translational Genomics Research Institute (TGen), and Origin Commercial Ventures.